143267-21-4

Basic information

• Product Name: (R)-2-<3-<(tert-butoxycarbonyl)amino>-2-oxo-1-pyrrolidinyl>-(S)-4-methylpentanoic acid pentafluorophenyl ester
• Synonyms: (R)-2-<3-<(tert-butoxycarbonyl)amino>-2-oxo-1-pyrrolidinyl>-(S)-4-methylpentanoic acid pentafluorophenyl ester
• CAS NO: 143267-21-4
• Molecular Weight: 480.432
• Mol File: 143267-21-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-2-<3-<(tert-butoxycarbonyl)amino>-2-oxo-1-pyrrolidinyl>-(S)-4-methylpentanoic acid pentafluorophenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-<3-<(tert-butoxycarbonyl)amino>-2-oxo-1-pyrrolidinyl>-(S)-4-methylpentanoic acid pentafluorophenyl ester(143267-21-4)
• EPA Substance Registry System: (R)-2-<3-<(tert-butoxycarbonyl)amino>-2-oxo-1-pyrrolidinyl>-(S)-4-methylpentanoic acid pentafluorophenyl ester(143267-21-4)

Safety Data

• Hazardous Substances Data: 143267-21-4(Hazardous Substances Data)

Upstream product

• 82611-46-9 N-(tert-butoxycarbonyl)-D-methionyl-L-leucine methyl ester 
• 5241-66-7 (R)-N-(tert-butoxycarbonyl)methionine 
• 124202-00-2 (R)-2-<3-<(tert-butoxycarbonyl)amino>-2-oxo-1-pyrrolidinyl>-(S)-4-methylpentanoic acid methyl ester 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 771-61-9 2,3,4,5,6-pentafluorophenol 
• 82611-48-1 (2S)-2-<(3R)-3-<(tert-butoxycarbonyl)amino>-2-oxopyrrolidin-1-yl>-4-methylpentanoic acid 

Downstream Products

• 137593-52-3 L-lysyl-L-α-aspartyl-L-seryl-L-phenylalanyl-L-valyl-(αS,3R)-3-amino-α-(2-methylpropyl)-2-oxo-1-pyrrolidineacetyl-L-methioninamide 

Relevant articles and documents

Conformationally Constrained Tachykinin Analogues: Potent and Highly Selective Neurokinin NK-2 Receptor Agonists

The design and synthesis of potent and selective neurokinin NK-2 receptor agonists 12 (GR64349) and 31 are described, together with structure-activity relationships for related analogues.Compound 12 (EC50 = 3.7 nM at NK-2 receptors in the rat colon; selectivity >1000- and >300-fold with respect to NK-1 and NK-3 receptors, respectively) was derived by incorporation of a Gly-Leu γ-lactam conformational constraint into the C-terminal region of the neurokinin A octapeptide analogue 3>-NKA(3-10).Compound 31 (EC50 = 15 nM in rat colon) contains a novel fused-bicyclicconstraint at the corresponding site in the substance P hexapeptide analogue 6>-SP(6-11).